Covidien Aneurysm Embolization Device Recall A Class I, FDA Says
This article was originally published in The Gray Sheet
Executive Summary
FDA tagged Covidien’s April 1 recall of its Pipeline aneurysm embolization devices and Alligator retrieval devices as a high risk, class I action.
You may also be interested in...
Covidien Initiates Aneurysm Device Recall
The voluntary recall of Covidien’s Pipeline aneurysm embolization device and Alligator retrieval devices is expected to have a slight negative effect on earnings in the second half of the year, but the impact could increase if it takes longer than expected to replace the affected products, the firm suggested.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.